<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918006</url>
  </required_header>
  <id_info>
    <org_study_id>VXA-CHAL-201</org_study_id>
    <nct_id>NCT02918006</nct_id>
  </id_info>
  <brief_title>A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine</brief_title>
  <official_title>Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009&#xD;
      (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based&#xD;
      Seasonal Influenza Vaccine and dsRNA Adjuvant (VXA-A1.1) to Healthy Adult Volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 randomized, placebo- and active-controlled, two-part study in which healthy&#xD;
      adult volunteers with low or undetectable pre-existing antibodies against&#xD;
      A/California/7/2009(H1N1) pdm09-like virus will be challenged with an influenza A/H1N1 human&#xD;
      challenge strain approximately 90 days after vaccination with a single dose of H1N1 HA&#xD;
      Adenoviral-vector based seasonal influenza vaccine and dsRNA adjuvant (VXA-A1.1), an&#xD;
      injectable QIV vaccine, and/or placebo.&#xD;
&#xD;
      An independent SMC will oversee the safety of the study.&#xD;
&#xD;
      To accommodate the limited size of the isolation unit that will be utilized for the challenge&#xD;
      and post-challenge sequestration period, subjects will move through the study (enrollment,&#xD;
      vaccination and challenge) sequentially in a total of 6 cohorts. Each cohort will randomize&#xD;
      30 subjects to obtain approximately 25 subjects per cohort for the challenge phase. Subjects&#xD;
      will be randomized in a ratio of 2:2:1 (VXA-A1.1: QIV: Placebo).&#xD;
&#xD;
      The study will be conducted in two parts.&#xD;
&#xD;
      Part A: Subjects will be randomized in a double-blinded manner to receive a single&#xD;
      administration of one of three treatment arms:&#xD;
&#xD;
        -  Arm 1: VXA-A1.1 oral vaccine + placebo IM&#xD;
&#xD;
        -  Arm 2: QIV IM injection + oral placebo&#xD;
&#xD;
        -  Arm 3: Placebo IM injection + oral placebo&#xD;
&#xD;
      Subjects will return to the site for ~8 visits and be contacted remotely at defined time&#xD;
      points to be followed for immunogenicity and safety during study Part A.&#xD;
&#xD;
      Part B: Subjects will be challenged with a wild-type influenza A H1 virus strain ~90 days&#xD;
      following vaccination. Blood samples will be collected to evaluate immunogenicity. Subjects&#xD;
      will remain in the isolation unit for 6 to 9 days post-challenge.&#xD;
&#xD;
      Following challenge, influenza symptoms and signs will be assessed during the sequestration&#xD;
      period. Blood samples and nasopharyngeal swab samples will be collected. Vital signs will be&#xD;
      measured every 4 hours during waking hours.&#xD;
&#xD;
      After release from the isolation unit subjects will return to the site 30 days&#xD;
      post-challenge. Part B will continue for purposes of collecting long term safety follow-up&#xD;
      (SAEs and AESIs/NOCIs) via phone contacts through 1 year post-vaccination (Day 365).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2016</start_date>
  <completion_date type="Actual">January 19, 2018</completion_date>
  <primary_completion_date type="Actual">May 19, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of influenza</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Oral Vaccine (VXA-A1.1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV IM Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral and IM Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VXA-A1.1</intervention_name>
    <description>Enteric coated oral vaccine tablet</description>
    <arm_group_label>Oral Vaccine (VXA-A1.1)</arm_group_label>
    <other_name>Oral H1N1 Ad5 Tableted Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone®</intervention_name>
    <description>Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection</description>
    <arm_group_label>QIV IM Injection</arm_group_label>
    <other_name>Fluzone Quadravalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product</description>
    <arm_group_label>Oral and IM Placebo</arm_group_label>
    <arm_group_label>QIV IM Injection</arm_group_label>
    <other_name>Enteric Coated Placebo Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Solution for Placebo IM Injection</intervention_name>
    <arm_group_label>Oral Vaccine (VXA-A1.1)</arm_group_label>
    <arm_group_label>Oral and IM Placebo</arm_group_label>
    <other_name>0.9% Sodium Chloride Injection, USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female volunteers aged 18 - 49 years, inclusive&#xD;
&#xD;
          2. Able to give written informed consent&#xD;
&#xD;
          3. Low pre-existing antibodies to the study vaccine&#xD;
&#xD;
          4. In general good health (no clinically significant health concerns)&#xD;
&#xD;
          5. Safety laboratory normal range or NCS (with few exceptions)&#xD;
&#xD;
          6. Body mass index between 17 and 35&#xD;
&#xD;
          7. Comprehension of the study requirements with ability and willingness to complete all&#xD;
             assessments and comply with scheduled visits and contacts&#xD;
&#xD;
          8. Female participants must have a negative pregnancy test at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receipt of any influenza vaccine within two years prior to study&#xD;
&#xD;
          2. Use of any investigational vaccine/adjuvanted vaccine within 8 weeks of study&#xD;
&#xD;
          3. Use of any investigational drug or device within 4 weeks of study&#xD;
&#xD;
          4. Use of any licensed vaccine within 30 days of study&#xD;
&#xD;
          5. Presence of significant uncontrolled medical or psychiatric illness within 3 months of&#xD;
             study&#xD;
&#xD;
          6. Clinically significant and/or protocol defined ECG abnormality&#xD;
&#xD;
          7. Positive serology for HIV-1 or HIV-2, or HBsAg or HCV antibodies&#xD;
&#xD;
          8. Cancer, or treatment for cancer, within 3 years of study&#xD;
&#xD;
          9. History of drug, alcohol or chemical abuse within 1 year&#xD;
&#xD;
         10. Receipt of blood or blood products within 6 months of study&#xD;
&#xD;
         11. Donation of blood within 4 weeks of study&#xD;
&#xD;
         12. Presence of a fever ≥ 38ºC measured orally at baseline&#xD;
&#xD;
         13. Stool sample with occult blood at screening&#xD;
&#xD;
         14. Positive urine drug screen for drugs of abuse at screening&#xD;
&#xD;
         15. Positive breath or urine alcohol test at screening or baseline&#xD;
&#xD;
         16. Consistent/habitual smoking within 2 months prior to vaccination&#xD;
&#xD;
         17. History of serious reactions to any vaccination such as anaphylaxis, respiratory&#xD;
             problems, Guillain-Barre syndrome, hives or abdominal pain&#xD;
&#xD;
         18. Asthma, bronchiectasis or chronic obstructive pulmonary disease&#xD;
&#xD;
         19. Any known allergy or intolerance to oseltamivir&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Liebowitz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vaxart, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <disposition_first_submitted>July 23, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 23, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 26, 2018</disposition_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

